Rockwell Medical - RMTI Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RMTI shares.
View RMTI analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 12-month price targets for Rockwell Medical's shares. Their RMTI share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 529.9% from the stock's current price.
View analysts price targets for RMTI or view top-rated stocks among Wall Street analysts.

Rockwell Medical's stock was trading at $4.51 at the start of the year. Since then, RMTI stock has decreased by 71.8% and is now trading at $1.27.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our RMTI earnings forecast.

Rockwell Medical, Inc. (NASDAQ:RMTI) announced its quarterly earnings results on Monday, August, 15th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.25. Rockwell Medical had a negative trailing twelve-month return on equity of 395.64% and a negative net margin of 43.33%. During the same quarter in the prior year, the firm posted ($0.99) earnings per share.

Rockwell Medical shares reverse split on Friday, May 13th 2022. The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

6 employees have rated Rockwell Medical Chief Executive Officer Robert L. Chioini on Glassdoor.com. Robert L. Chioini has an approval rating of 22% among the company's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

Rockwell Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Richmond Brothers Inc. (6.79%), Perkins Capital Management Inc. (3.78%), Verdence Capital Advisors LLC (0.76%), Millennium Management LLC (0.52%), Renaissance Technologies LLC (0.37%) and SkyOak Wealth LLC (0.21%). Insiders that own company stock include David S Richmond and Russell H Ellison.
View institutional ownership trends.

Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMTI stock can currently be purchased for approximately $1.27.

Rockwell Medical (NASDAQ:RMTI) has a market capitalization of $11.95 million and generates $61.93 million in revenue each year.

The company employs 300 workers across the globe.

Rockwell Medical's mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The official website for the company is www.rockwellmed.com. The company can be reached via phone at (248) 960-9009, via email at invest@rockwellmed.com, or via fax at 248-960-9119.